文献速递呼吸危重症与机械通气

ECMO期间输注间充质干细胞导致氧合器性能快速下降

Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance.
PubMed 文献 · Thorax · 2018-04-05

研究利用体外ECMO模型评估ECMO运行期间血管内输注间充质干细胞(MSCs)对膜氧合器功能的影响。临床级MSCs的加入导致回路流量下降、跨氧合器压力梯度升高,免疫组化显示大量MSCs黏附于膜氧合器纤维。结果提示ECMO期间MSC治疗可能存在潜在危害。

要点

  • ECMO期间输注MSCs可致氧合器回路流量下降、跨膜压力梯度升高。
  • MSCs大量黏附于膜氧合器纤维,可能损害氧合器功能。
  • 既往ARDS的MSC早期临床试验均排除ECMO支持患者。

核心结论

  • ECMO期间血管内输注MSCs可能对膜氧合器功能产生不良影响。

研究设计与样本

  • 研究采用体外ECMO模型,比较加入临床级MSCs与对照组的氧合器功能。

主要发现

  • 240分钟时,MSCs组回路流量为0.6±0.35 L min-1,低于对照组的4.12±0.03 L min-1。
  • 240分钟时,MSCs组跨氧合器压力梯度为101±9 mmHg,高于对照组的21±4 mmHg。
  • 免疫组化分析显示大量MSCs黏附于膜氧合器纤维。

临床怎么用

  • 提示在ECMO支持患者中开展MSC治疗需警惕氧合器功能受损风险。
  • 后续临床转化研究应评估MSC输注与ECMO兼容性及给药策略。

局限性

  • 证据来自体外ECMO模型,尚不能直接外推至临床患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mesenchymal stem cells (MSCs) have attracted attention as a potential therapy for Acute Respiratory Distress Syndrome (ARDS). At the same time, the use of extracorporeal membrane oxygenation (ECMO) has increased among patients with severe ARDS. To date, early clinical trials of MSCs in ARDS have excluded patients supported by ECMO. Here we provide evidence from an ex-vivo model of ECMO to suggest that the intravascular administration of MSCs during ECMO may adversely impact the function of a membrane oxygenator. The addition of clinical grade MSCs resulted in a reduction of flow through the circuit in comparison to controls (0.6 ±0.35 L min-1vs 4.12 ± 0.03 L min-1, at 240 minutes) and an increase in the transoygenator pressure gradient (101±9 mmHg vs 21±4 mmHg, at 240 minutes). Subsequent immunohistochemistry analysis demonstrated quantities of MSCs highly adherent to membrane oxygenator fibres. This study highlights the potential harm associated with MSC therapy during ECMO and suggests further areas of research required to advance the translation of cell therapy in this population.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Millar JE, von Bahr V, Malfertheiner MV, et al. Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance. Thorax. 2018. PMID: 29622695. doi:10.1136/thoraxjnl-2017-211439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。